
<!DOCTYPE html>
<html>
<meta charset="UTF-8">
<head>
  <title>Most Relevant Terms per Topic</title>

<style>
table {
  font-family: "Trebuchet MS", Arial, Helvetica, sans-serif;
  border-collapse: collapse;
  width: 100%;
}

td, th {
  border: 1px solid #ddd;
  padding: 8px;
}

td:nth-child(even){background-color: #f2f2f2;}

td:hover {background-color: #ddd;}

th {
  padding-top: 12px;
  padding-bottom: 12px;
  text-align: left;
  background-color: #0099FF;
  color: white;
}
</style>

</head>
<body>
<h2>Most Relevant Terms per Topic</h2>
<h3>Abstracts with Biological Entities (English) - 75 Topics / Sub-Topic Model 15</h3>
<table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th></th>
      <th><a href="Topic_01.html" target="_blank">Topic 1</a></th>
      <th><a href="Topic_02.html" target="_blank">Topic 2</a></th>
      <th><a href="Topic_03.html" target="_blank">Topic 3</a></th>
      <th><a href="Topic_04.html" target="_blank">Topic 4</a></th>
      <th><a href="Topic_05.html" target="_blank">Topic 5</a></th>
      <th><a href="Topic_06.html" target="_blank">Topic 6</a></th>
      <th><a href="Topic_07.html" target="_blank">Topic 7</a></th>
      <th><a href="Topic_08.html" target="_blank">Topic 8</a></th>
      <th><a href="Topic_09.html" target="_blank">Topic 9</a></th>
      <th><a href="Topic_10.html" target="_blank">Topic 10</a></th>
      <th><a href="Topic_11.html" target="_blank">Topic 11</a></th>
      <th><a href="Topic_12.html" target="_blank">Topic 12</a></th>
      <th><a href="Topic_13.html" target="_blank">Topic 13</a></th>
      <th><a href="Topic_14.html" target="_blank">Topic 14</a></th>
      <th><a href="Topic_15.html" target="_blank">Topic 15</a></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>1</th>
      <td>drugs</td>
      <td>antiviral</td>
      <td>in vitro</td>
      <td>screening</td>
      <td>coronavirus</td>
      <td>peptides</td>
      <td>delivery</td>
      <td>influenza</td>
      <td>inhibitors</td>
      <td>ebola</td>
      <td>hepatitis</td>
      <td>agonists</td>
      <td>JEV</td>
      <td>UPS</td>
      <td>mabs</td>
    </tr>
    <tr>
      <th>2</th>
      <td>clinical</td>
      <td>viral</td>
      <td>vitro</td>
      <td>discovery</td>
      <td>sars-cov-2</td>
      <td>antimicrobial</td>
      <td>rnai</td>
      <td>M2</td>
      <td>norovirus</td>
      <td>EBOV</td>
      <td>DNA</td>
      <td>diabetes</td>
      <td>RSV</td>
      <td>ubiquitin</td>
      <td>monoclonal</td>
    </tr>
    <tr>
      <th>3</th>
      <td>drug</td>
      <td>viruses</td>
      <td>infection</td>
      <td>drug</td>
      <td>COVID-19</td>
      <td>natural</td>
      <td>sirna</td>
      <td>IAV</td>
      <td>protease</td>
      <td>GS-5734</td>
      <td>simplex</td>
      <td>derivatives</td>
      <td>diarrhea</td>
      <td>IFN</td>
      <td>antibodies</td>
    </tr>
    <tr>
      <th>4</th>
      <td>diseases</td>
      <td>virus</td>
      <td>vivo</td>
      <td>virtual</td>
      <td>sars-cov</td>
      <td>peptide</td>
      <td>interference</td>
      <td>H5N1</td>
      <td>molecule</td>
      <td>ebola virus</td>
      <td>HCV</td>
      <td>ferroquine</td>
      <td>encephalitis</td>
      <td>oncolytic</td>
      <td>HCV</td>
    </tr>
    <tr>
      <th>5</th>
      <td>development</td>
      <td>host</td>
      <td>effect</td>
      <td>compounds</td>
      <td>SARS</td>
      <td>amps</td>
      <td>antisense</td>
      <td>H1N1</td>
      <td>enzyme</td>
      <td>EVD</td>
      <td>HRV</td>
      <td>antimalarials</td>
      <td>assay</td>
      <td>proteasome</td>
      <td>CQ</td>
    </tr>
    <tr>
      <th>6</th>
      <td>therapeutic</td>
      <td>replication</td>
      <td>in vivo</td>
      <td>docking</td>
      <td>syndrome</td>
      <td>natural products</td>
      <td>gene</td>
      <td>pandemic</td>
      <td>3clpro</td>
      <td>fatality</td>
      <td>cytomegalovirus</td>
      <td>malaria</td>
      <td>VEEV</td>
      <td>dubs</td>
      <td>monoclonal antibodies</td>
    </tr>
    <tr>
      <th>7</th>
      <td>review</td>
      <td>antiviral drugs</td>
      <td>activity</td>
      <td>lead</td>
      <td>mers-cov</td>
      <td>products</td>
      <td>sirnas</td>
      <td>neuraminidase</td>
      <td>small molecule</td>
      <td>niv</td>
      <td>HCMV</td>
      <td>effects</td>
      <td>SCV</td>
      <td>signaling</td>
      <td>HCQ</td>
    </tr>
    <tr>
      <th>8</th>
      <td>studies</td>
      <td>development</td>
      <td>cells</td>
      <td>virtual screening</td>
      <td>respiratory</td>
      <td>bacteria</td>
      <td>nucleic</td>
      <td>avian</td>
      <td>inhibitor</td>
      <td>africa</td>
      <td>infections</td>
      <td>antimalarial</td>
      <td>aureus</td>
      <td>CEP</td>
      <td>mab</td>
    </tr>
    <tr>
      <th>9</th>
      <td>current</td>
      <td>viral infections</td>
      <td>chloroquine</td>
      <td>silico</td>
      <td>coronaviruses</td>
      <td>activities</td>
      <td>drug delivery</td>
      <td>oseltamivir</td>
      <td>x-ray</td>
      <td>favipiravir</td>
      <td>herpes</td>
      <td>niclosamide</td>
      <td>rotavirus</td>
      <td>oncolytic viruses</td>
      <td>antibody</td>
    </tr>
    <tr>
      <th>10</th>
      <td>trials</td>
      <td>infections</td>
      <td>results</td>
      <td>in silico</td>
      <td>middle</td>
      <td>antibiotics</td>
      <td>RNA</td>
      <td>seasonal</td>
      <td>proteases</td>
      <td>fever</td>
      <td>HBV</td>
      <td>HCT</td>
      <td>fda-approved</td>
      <td>cancer</td>
      <td>p7</td>
    </tr>
    <tr>
      <th>11</th>
      <td>recent</td>
      <td>RNA</td>
      <td>model</td>
      <td>drug candidates</td>
      <td>east</td>
      <td>bacterial</td>
      <td>oligonucleotides</td>
      <td>neuraminidase inhibitors</td>
      <td>gastroenteritis</td>
      <td>conducted</td>
      <td>HEV</td>
      <td>lymphatic</td>
      <td>EV71</td>
      <td>stroke</td>
      <td>escape</td>
    </tr>
    <tr>
      <th>12</th>
      <td>therapies</td>
      <td>antivirals</td>
      <td>treatment</td>
      <td>target</td>
      <td>2019</td>
      <td>marine</td>
      <td>rna interference</td>
      <td>influenza viruses</td>
      <td>rdrp</td>
      <td>amodiaquine</td>
      <td>nucleoside</td>
      <td>anthelmintic</td>
      <td>S.</td>
      <td>DUB</td>
      <td>htas</td>
    </tr>
    <tr>
      <th>13</th>
      <td>patients</td>
      <td>human</td>
      <td>inhibitory</td>
      <td>chemical</td>
      <td>acute respiratory syndrome</td>
      <td>antibiotic</td>
      <td>systems</td>
      <td>anti-influenza</td>
      <td>active site</td>
      <td>case fatality</td>
      <td>hiv infections</td>
      <td>NM</td>
      <td>CPV</td>
      <td>serms</td>
      <td>cocktail</td>
    </tr>
    <tr>
      <th>14</th>
      <td>animal</td>
      <td>antiviral agents</td>
      <td>showed</td>
      <td>design</td>
      <td>remdesivir</td>
      <td>sources</td>
      <td>mirnas</td>
      <td>influenza a virus</td>
      <td>scaffolds</td>
      <td>nipah</td>
      <td>NS5B</td>
      <td>p-pd</td>
      <td>SMA</td>
      <td>1996</td>
      <td>antibody-based</td>
    </tr>
    <tr>
      <th>15</th>
      <td>clinical trials</td>
      <td>proteins</td>
      <td>study</td>
      <td>computational</td>
      <td>MERS</td>
      <td>microbial</td>
      <td>targeted</td>
      <td>amantadine</td>
      <td>protease inhibitors</td>
      <td>BCX4430</td>
      <td>syncytial</td>
      <td>antimalarial drugs</td>
      <td>cryptosporidiosis</td>
      <td>tumor</td>
      <td>mutants</td>
    </tr>
    <tr>
      <th>16</th>
      <td>efficacy</td>
      <td>entry</td>
      <td>inhibited</td>
      <td>drug discovery</td>
      <td>china</td>
      <td>resistance</td>
      <td>antisense oligonucleotides</td>
      <td>channel</td>
      <td>macrocyclic</td>
      <td>nvis</td>
      <td>common</td>
      <td>lipid</td>
      <td>growth</td>
      <td>pharmacological</td>
      <td>epitopes</td>
    </tr>
    <tr>
      <th>17</th>
      <td>treatment</td>
      <td>drugs</td>
      <td>antiviral</td>
      <td>protein</td>
      <td>2019-ncov</td>
      <td>properties</td>
      <td>ARDS</td>
      <td>H3N2</td>
      <td>noroviruses</td>
      <td>arenavirus</td>
      <td>analogues</td>
      <td>effects of</td>
      <td>cryptosporidium</td>
      <td>antitumor</td>
      <td>genotype</td>
    </tr>
    <tr>
      <th>18</th>
      <td>approaches</td>
      <td>targets</td>
      <td>concentrations</td>
      <td>identification</td>
      <td>acute</td>
      <td>organisms</td>
      <td>vectors</td>
      <td>diphyllin</td>
      <td>structure-based</td>
      <td>countermeasures</td>
      <td>ii</td>
      <td>metabolism</td>
      <td>breast</td>
      <td>anti-cancer</td>
      <td>SL</td>
    </tr>
    <tr>
      <th>19</th>
      <td>disease</td>
      <td>agents</td>
      <td>demonstrated</td>
      <td>pharmacophore</td>
      <td>severe</td>
      <td>fungi</td>
      <td>material</td>
      <td>pandemics</td>
      <td>small</td>
      <td>propose</td>
      <td>herpes simplex virus</td>
      <td>side</td>
      <td>s. aureus</td>
      <td>ifn-ω</td>
      <td>positions</td>
    </tr>
    <tr>
      <th>20</th>
      <td>approved</td>
      <td>ZIKV</td>
      <td>mouse</td>
      <td>targets</td>
      <td>emetine</td>
      <td>activity</td>
      <td>interfering</td>
      <td>influenza virus</td>
      <td>substrate</td>
      <td>outbreaks</td>
      <td>cold</td>
      <td>dual</td>
      <td>children</td>
      <td>parkinson</td>
      <td>microbial diseases</td>
    </tr>
    <tr>
      <th>21</th>
      <td>treat</td>
      <td>viral diseases</td>
      <td>inhibition</td>
      <td>HTS</td>
      <td>cov</td>
      <td>plants</td>
      <td>users</td>
      <td>influenza virus infection</td>
      <td>site</td>
      <td>BSL-4</td>
      <td>EV-D68</td>
      <td>AD</td>
      <td>library</td>
      <td>enzymes</td>
      <td>cyclophilin</td>
    </tr>
    <tr>
      <th>22</th>
      <td>promising</td>
      <td>resistance</td>
      <td>antiviral activity</td>
      <td>high-throughput</td>
      <td>middle east respiratory syndrome coronavirus</td>
      <td>extracts</td>
      <td>SUPPLEMENTARY</td>
      <td>hemagglutinin</td>
      <td>3CL</td>
      <td>DEF201</td>
      <td>i.e.</td>
      <td>immunomodulators</td>
      <td>japanese</td>
      <td>immunity</td>
      <td>genotypes</td>
    </tr>
    <tr>
      <th>23</th>
      <td>provide</td>
      <td>HIV</td>
      <td>effective</td>
      <td>molecular</td>
      <td>pandemic</td>
      <td>antimicrobial peptides</td>
      <td>authorized</td>
      <td>SP-D</td>
      <td>structure</td>
      <td>SFTSV</td>
      <td>half</td>
      <td>bcl-2i</td>
      <td>SMN</td>
      <td>cellular</td>
      <td>DMD</td>
    </tr>
    <tr>
      <th>24</th>
      <td>models</td>
      <td>immunodeficiency</td>
      <td>virus</td>
      <td>process</td>
      <td>spread</td>
      <td>plant</td>
      <td>supplementary</td>
      <td>HA</td>
      <td>acute gastroenteritis</td>
      <td>tpcs</td>
      <td>chronic</td>
      <td>tetracyclines</td>
      <td>ouabain</td>
      <td>bortezomib</td>
      <td>unborn</td>
    </tr>
    <tr>
      <th>25</th>
      <td>potential</td>
      <td>cycle</td>
      <td>agent</td>
      <td>drug design</td>
      <td>drugs</td>
      <td>venoms</td>
      <td>version</td>
      <td>influenza pandemic</td>
      <td>picornavirus</td>
      <td>containment</td>
      <td>hepatitis b</td>
      <td>plasmodium</td>
      <td>bactericidal</td>
      <td>cancer therapy</td>
      <td>anti-adhesion</td>
    </tr>
    <tr>
      <th>26</th>
      <td>treating</td>
      <td>targeting</td>
      <td>identified</td>
      <td>throughput</td>
      <td>ritonavir</td>
      <td>scorpion</td>
      <td>online</td>
      <td>export</td>
      <td>anti-norovirus</td>
      <td>boosted</td>
      <td>HSV</td>
      <td>NAFLD</td>
      <td>SMD1168H-TOPOI</td>
      <td>modulators</td>
      <td>daas</td>
    </tr>
    <tr>
      <th>27</th>
      <td>action</td>
      <td>broad-spectrum</td>
      <td>nitazoxanide</td>
      <td>affinity</td>
      <td>lopinavir</td>
      <td>environment</td>
      <td>facilitate</td>
      <td>2009</td>
      <td>indole</td>
      <td>biosafety</td>
      <td>dna viruses</td>
      <td>melanoma</td>
      <td>poliovirus</td>
      <td>kinases</td>
      <td>GT3</td>
    </tr>
    <tr>
      <th>28</th>
      <td>mortality</td>
      <td>viral replication</td>
      <td>recombinant</td>
      <td>ligand</td>
      <td>mpro</td>
      <td>antifungal</td>
      <td>systemic</td>
      <td>influenza virus infections</td>
      <td>design</td>
      <td>SFTS</td>
      <td>©</td>
      <td>glucose</td>
      <td>closantel</td>
      <td>receptor</td>
      <td>GT4</td>
    </tr>
    <tr>
      <th>29</th>
      <td>treatments</td>
      <td>vaccines</td>
      <td>ribavirin</td>
      <td>drug discovery process</td>
      <td>acute respiratory syndrome coronavirus</td>
      <td>antimicrobial activity</td>
      <td>therapeutic</td>
      <td>AP3</td>
      <td>small molecule inhibitors</td>
      <td>proofreading</td>
      <td>iii</td>
      <td>macrophages</td>
      <td>parasite</td>
      <td>ubiquitin pathway</td>
      <td>interferon-free</td>
    </tr>
    <tr>
      <th>30</th>
      <td>research</td>
      <td>life</td>
      <td>concentration</td>
      <td>libraries</td>
      <td>proteinase</td>
      <td>antibacterial</td>
      <td>therapy</td>
      <td>v-atpase</td>
      <td>norovirus infection</td>
      <td>west africa</td>
      <td>ENF</td>
      <td>DPP-4</td>
      <td>enterovirus 71</td>
      <td>type i ifn</td>
      <td>immunoglobulin</td>
    </tr>
    <tr>
      <th>31</th>
      <td>including</td>
      <td>infection</td>
      <td>cell</td>
      <td>structure</td>
      <td>hcov</td>
      <td>candida</td>
      <td>online version</td>
      <td>drug-resistant</td>
      <td>structural</td>
      <td>haemorrhagic</td>
      <td>GA</td>
      <td>side effects</td>
      <td>camptothecin</td>
      <td>innate immunity</td>
      <td>immune</td>
    </tr>
    <tr>
      <th>32</th>
      <td>advances</td>
      <td>important</td>
      <td>CHIKV</td>
      <td>candidates</td>
      <td>spike</td>
      <td>lectins</td>
      <td>barriers</td>
      <td>T20</td>
      <td>replicon</td>
      <td>ebola virus disease</td>
      <td>ARB</td>
      <td>swine</td>
      <td>ML-HSA</td>
      <td>S6</td>
      <td>total</td>
    </tr>
    <tr>
      <th>33</th>
      <td>agents</td>
      <td>factors</td>
      <td>FCV</td>
      <td>active</td>
      <td>middle east respiratory syndrome</td>
      <td>antimicrobial drugs</td>
      <td>cpps</td>
      <td>drug-resistant viruses</td>
      <td>WNV</td>
      <td>post-exposure</td>
      <td>ribavirin</td>
      <td>MS</td>
      <td>multiplication</td>
      <td>proteasome inhibitors</td>
      <td>transduced</td>
    </tr>
    <tr>
      <th>34</th>
      <td>overview</td>
      <td>polymerase</td>
      <td>μm</td>
      <td>based</td>
      <td>main</td>
      <td>due</td>
      <td>INFORMATION</td>
      <td>shedding</td>
      <td>SERT</td>
      <td>RVFV</td>
      <td>chronic hepatitis b</td>
      <td>enterocyte</td>
      <td>equine</td>
      <td>activators</td>
      <td>pre-exposure</td>
    </tr>
    <tr>
      <th>35</th>
      <td>made</td>
      <td>viral proteins</td>
      <td>reduction</td>
      <td>compound</td>
      <td>mers-cov.</td>
      <td>found</td>
      <td>vascular</td>
      <td>mtb</td>
      <td>crystal</td>
      <td>arenaviruses</td>
      <td>CMV</td>
      <td>rheumatoid</td>
      <td>anti-ev71</td>
      <td>ifn‐β</td>
      <td>government</td>
    </tr>
    <tr>
      <th>36</th>
      <td>numerous</td>
      <td>human immunodeficiency virus</td>
      <td>feline</td>
      <td>hits</td>
      <td>homology</td>
      <td>natural product</td>
      <td>liposomes</td>
      <td>DP2392-E10</td>
      <td>crystallography</td>
      <td>case</td>
      <td>periodicals</td>
      <td>anti-trypanosomal</td>
      <td>TI</td>
      <td>OV</td>
      <td>ebovs</td>
    </tr>
    <tr>
      <th>37</th>
      <td>effective</td>
      <td>target</td>
      <td>test</td>
      <td>identified</td>
      <td>wuhan</td>
      <td>antimicrobial activities</td>
      <td>organs</td>
      <td>viruses</td>
      <td>JNK</td>
      <td>chlorpromazine</td>
      <td>wiley</td>
      <td>GALT</td>
      <td>platelet</td>
      <td>FAN</td>
      <td>IND</td>
    </tr>
    <tr>
      <th>38</th>
      <td>evidence</td>
      <td>treatment</td>
      <td>antiviral effect</td>
      <td>3D</td>
      <td>rapidly</td>
      <td>SM21</td>
      <td>directed</td>
      <td>hiv-infected</td>
      <td>catalytic</td>
      <td>cifn-α</td>
      <td>formally</td>
      <td>steatosis</td>
      <td>sitafloxacin</td>
      <td>TET</td>
      <td>interferon-based</td>
    </tr>
    <tr>
      <th>39</th>
      <td>success</td>
      <td>genetic</td>
      <td>load</td>
      <td>approach</td>
      <td>protease</td>
      <td>eval418</td>
      <td>lung</td>
      <td>epithelial</td>
      <td>norovirus 3cl protease</td>
      <td>MHV</td>
      <td>res</td>
      <td>lupus</td>
      <td>drug library</td>
      <td>dopamine</td>
      <td>u.s. food and drug administration</td>
    </tr>
    <tr>
      <th>40</th>
      <td>—</td>
      <td>zika</td>
      <td>effects</td>
      <td>programs</td>
      <td>anti-coronavirus</td>
      <td>gossypol</td>
      <td>targeting</td>
      <td>influenza infection</td>
      <td>ncrna</td>
      <td>nipah virus</td>
      <td>immediate-early</td>
      <td>apoptosis</td>
      <td>projects</td>
      <td>tumors</td>
      <td>cyclophilin inhibitors</td>
    </tr>
    <tr>
      <th>41</th>
      <td>past</td>
      <td>dengue</td>
      <td>griffithsin</td>
      <td>learning</td>
      <td>sars-cov infection</td>
      <td>present</td>
      <td>target</td>
      <td>hiv-1 strains</td>
      <td>focused</td>
      <td>curve</td>
      <td>med</td>
      <td>rheumatoid arthritis</td>
      <td>EV-71</td>
      <td>parkinson’s disease</td>
      <td>invariant</td>
    </tr>
    <tr>
      <th>42</th>
      <td>effects</td>
      <td>genome</td>
      <td>prevented</td>
      <td>secondary</td>
      <td>mers-cov infection</td>
      <td>infectious</td>
      <td>expression</td>
      <td>bafilomycin</td>
      <td>genus</td>
      <td>ebolavirus</td>
      <td>conjugate</td>
      <td>tβ4</td>
      <td>retrocyclins</td>
      <td>RAS</td>
      <td>HDL</td>
    </tr>
    <tr>
      <th>43</th>
      <td>safety</td>
      <td>inhibitors</td>
      <td>therapeutic</td>
      <td>experimentally</td>
      <td>CVL218</td>
      <td>agents</td>
      <td>vehicles</td>
      <td>pandemic influenza</td>
      <td>βglu</td>
      <td>ntds</td>
      <td>VZV</td>
      <td>activating</td>
      <td>breast cancer</td>
      <td>kinase</td>
      <td>biothreat</td>
    </tr>
    <tr>
      <th>44</th>
      <td>summarize</td>
      <td>antiviral therapeutics</td>
      <td>vero</td>
      <td>identify</td>
      <td>sars-cov.</td>
      <td>polyether</td>
      <td>nucleic acids</td>
      <td>iavs</td>
      <td>viral protease</td>
      <td>TPC2</td>
      <td>colds</td>
      <td>aips</td>
      <td>71</td>
      <td>anticancer</td>
      <td>federal</td>
    </tr>
    <tr>
      <th>45</th>
      <td>molecules</td>
      <td>play</td>
      <td>replication</td>
      <td>billion</td>
      <td>spreading</td>
      <td>antiviral properties</td>
      <td>therapeutic molecules</td>
      <td>slices</td>
      <td>dipeptidyl</td>
      <td>LASV</td>
      <td>recipients</td>
      <td>tα1</td>
      <td>reporter</td>
      <td>hematological</td>
      <td>couples</td>
    </tr>
    <tr>
      <th>46</th>
      <td>repurposed</td>
      <td>enveloped</td>
      <td>disease</td>
      <td>optimized</td>
      <td>hiv-1 protease inhibitors</td>
      <td>pomegranate</td>
      <td>ill</td>
      <td>PAM</td>
      <td>SP600125</td>
      <td>dosed</td>
      <td>no.</td>
      <td>GLP-1</td>
      <td>hit</td>
      <td>CXCR4</td>
      <td>REGN3051</td>
    </tr>
    <tr>
      <th>47</th>
      <td>approval</td>
      <td>viral life cycle</td>
      <td>ifn-α</td>
      <td>chemical libraries</td>
      <td>2020</td>
      <td>scorpions</td>
      <td>deliver</td>
      <td>TCAD</td>
      <td>probiotics</td>
      <td>lethal</td>
      <td>hepatitis c virus</td>
      <td>body weight</td>
      <td>motor</td>
      <td>endolysosomal</td>
      <td>adhesins</td>
    </tr>
    <tr>
      <th>48</th>
      <td>clinical studies</td>
      <td>potential</td>
      <td>FIP</td>
      <td>NMR</td>
      <td>interactome</td>
      <td>efflux</td>
      <td>designed</td>
      <td>verdinexor</td>
      <td>sars-cov-2 3clpro</td>
      <td>rates</td>
      <td>GS‐6620</td>
      <td>poly</td>
      <td>screening</td>
      <td>ischemic</td>
      <td>REGN3048</td>
    </tr>
    <tr>
      <th>49</th>
      <td>context</td>
      <td>antiviral compounds</td>
      <td>cytotoxicity</td>
      <td>active compounds</td>
      <td>ivermectin</td>
      <td>ctry2459</td>
      <td>messenger</td>
      <td>classes</td>
      <td>norovirus 3c-like protease</td>
      <td>severe</td>
      <td>vi</td>
      <td>hopping</td>
      <td>strain</td>
      <td>ovs</td>
      <td>AO</td>
    </tr>
    <tr>
      <th>50</th>
      <td>benefits</td>
      <td>host factors</td>
      <td>symptoms</td>
      <td>protein targets</td>
      <td>signatures</td>
      <td>natural sources</td>
      <td>ribozymes</td>
      <td>strains</td>
      <td>norovirus infections</td>
      <td>outbreak</td>
      <td>cidofovir</td>
      <td>absorption</td>
      <td>high-throughput</td>
      <td>radiation</td>
      <td>restore</td>
    </tr>
  </tbody>
</table>
</body>
</html>
